(SIBLING), bone sialoprotein (BSP) - Semantic Scholar

Apr 9, 2009 - Bradshaw AD, Sage EH (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury.

Author manuscript, published in "Osteoporosis International (2009) epub ahead of print" DOI : 10.1007/s00198-009-0869-2

Role of the Small Integrin Binding Ligand N­linked Glycoprotein  (SIBLING),   bone   sialoprotein   (BSP)   in   bone   development   and  remodeling.

Luc Malaval1*, Jane E Aubin2 and Laurence Vico1

ujm-00374655, version 1 - 9 Apr 2009

1 : INSERM U890­LBTO, 42023 Saint­Etienne, France ; IFR 143, 42023 Saint­Etienne,  France ; Université Jean Monnet, 42023 Saint­Etienne, France. 2 : Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

* : Corrresponding author :

INSERM U890­LBTO IFR 143­IFRESIS Université Jean Monnet Faculté de Médecine 15. rue A. Paré  42023 St Etienne Cedex 02  France

T. 33­4­77­42­14­44


Fax 33­4­77­57­55­72

ujm-00374655, version 1 - 9 Apr 2009

E­mail: [email protected]­st­etienne.fr


Between cell and mineral ­ the SIBLINGs The « small, integrin binding ligand, N­linked glycoprotein » family (SIBLINGs, [1]) group  osteopontin   (OPN),   bone   sialoprotein   (BSP),   dentin   sialophosphoprotein   (DSPP),   dentin  matrix protein­1 (DMP­1) and matrix extracellular glycohosphoprotein (MEPE).  The genes  for this family are aligned on a portion of human chromosome 4 (mouse chromosome 5),  within   a   «  Bone Gene Cluster  » [2, 3] grouping other  genes  of bone interest.  Molecular  evolution   studies  [4,  5] suggest  that  SIBLINGs,  along  with  enamelins   and other  proteins 

ujm-00374655, version 1 - 9 Apr 2009

found   in   milk   (caseins)   and   saliva   (statherin),   form   a  «  Secretory   Calcium   binding  PhosphoProteins  » (SCPP) family  [4], sharing as a common ancestor Hevin [6], and more  precisely the long N­terminal domain that distinguishes it from the related protein SPARC  (secreted   protein,   acidic   and   rich   in   cystein)/Osteonectin   [7].   The   SCPP   share   a   flexible  structure, and many contain numerous acidic aminoacid residues, which favor interactions  with   crystals  (review  in [8]). The  SIBLINGs, more  specifically,  have acidic  pI (with  the  exception of MEPE), and display in their sequence a proline­rich stretch (basic), consensus  sites for casein­kinase, an arginine­glycine­aspartic acid (RGD) sequence binding intergrin  family receptors, and (apart for BSP) one or several ASARM (acidic serine­aspartate rich  MEPE associated) peptides, which have a high affinity for hydroxyapatite and appear to be  potent regulators of mineralization [9, 10]. The SIBLINGs also display a high degree of post­ translational modification (phosphorylation, sulfatation and/or glycosylation) which varies for  a given protein in time (cellular differentiation) and space (tissue), and directly affects their  biological functions (review in [11]). In bone, the SIBLINGs are expressed by cells of the  osteoblast lineage, DMP­1 and MEPE being mostly restricted to osteocytes. OPN and BSP at  least are also expressed by hypertrophic chondrocytes and osteoclasts. SIBLINGs are also  present   in   multiple   non­mineralized   tissues,   expecially   with   secretory   functions   (salivary 


glands,   kidney,   [12,   13])   and   by   cancer   cells   in   which   they   favor   metastatic   processes,  particularly targeting bone (review in [14]).

Regulators of  matrix mineralization and bone remodeling DMP1  and MEPE appear as prominent regulators of mineralization. DMP1 knockout mice  display massive osteomalacia [15], at least in part indirectly, through impaired maturation of  osteocytes, which is necessary to proper mineralization, and also increased levels of FGF­23 

ujm-00374655, version 1 - 9 Apr 2009

(a  powerful negative  regulator  of phosphatemia  [16]) as well as  MEPE [17]. In contrast,  MEPE   knockout   increases   bone   mass   [18].   A   major   inhibitory   factor   of   mineralisation  (“Minhibin”, [19]) is the ASARM peptide (review in [9]), which is cleaved by cathepsins B  and K from MEPE and DMP­1, circulates in blood and is responsible for the high levels of  osteomalacia   observed   in   hypophosphatemia   [10].   The   most   studied   of   SIBLINGs,   OPN  (review   in   [20]),   is   a   ubiquitous   protein   whose   functions   range   from   inflammation   to  lactation, and which has been called a cytokine [21]. The bones of OPN knockout mice [22]  display   a   cell­autonomous   defect   of   osteoclast   recruitment   and   activity.   This   results   in  resorption defect, a higher trabecular bone mass in mutant bones, and a lack of response to  challenges increasing bone loss, such as ovariectomy [23] and hindlimb unloading, a model of  disuse bone loss [24]. Interacting with bone cells through both integrins (mostly α vβ 3) and  CD44,   OPN   thus   appears   directly   involved   in   the   regulation   of   cell   adhesion   and   bone  remodeling. Interestingly, OPN ­/­ bone is also hypermineralized, and lack of OPN partly  compensates osteomalacia in mice with a knockout of tissue non specific alkaline phosphatase  (TNALP),   confirming   that   OPN   also   plays   a   part   as   a  physiological   inhibitor   of   organic  matrix mineralization [25]. Considering that OPN and BSP (review in [26]) are the two major SIBLINGs expressed in bone forming osteoblasts, it is important to clarify the specificities


and redundancies in their respective functions.

The roles of BSP ­ insights from a mild phenotype knockout We generated BSP knockout (BSP-/-) mice through genetic recombination, and studied both  their basal phenotype and their response to challenges [27]. BSP-/- mice develop and grow normally, but remain smaller than their wild-type counterparts throughout life (Figure 1a, b). Cortical bone is thinner in young mutant mice (Figure 1c) and progressively increases with

ujm-00374655, version 1 - 9 Apr 2009

age to reach wild type values. BSP-/- mice display early, mild matrix hypomineralization (~5% in adults), which also progressively normalizes in older mice. Previous  in vitro  data  already  showed that BSP promotes the formation of hydroxyapatite crystals, contrarily  to  OPN [28]. BSP is highly abundant in woven, primary bone [29] where it would play a direct  part in mineralization, in association with an unrelated aggregating glycoprotein, bone acidic  glycoprotein­75 [30, 31]. Indeed, primary marrow cultures from BSP­/­ bones grow normal  numbers   of   TNALP+   (=osteoblast   lineage)   colonies   but   reduced   numbers   of   mineralized  nodules respective to wild type controls. The progressive recovery of mineralization degree in  older BSP­/­ mice also suggests a role in mineralization focused on primary bone. However,  BSP­/­ marrow cultures also display reduced expression of osteoblast­related genes, such as  type   I   collagen,   indicating   that,   beyond   crystal   nucleation,   lack   of   BSP   also   affects  mineralization   through   alterations   of   the   osteoblast   phenotype   and   matrix  amount/composition. This confirms previous work with recombinant proteins, showing the  importance   of   BSP,   specifically   the   RGD   containing   portion,   for   osteoblast   phenotypic  regulation [32]. Osteoblast phenotype impairment could also explain why the bone formation  rate   (BFR)   of   secondary,   trabecular   bone   of   BSP­/­   mice   is   very   low   (Figure   1d),   with  reduced osteoblast surfaces and increased osteoid surfaces and thickness. We challenged the 


ability of mutant mice to repair bone with a cortical defect model. After drilling a hole in the  femur proximal to the knee articulation, repair was folllowed up through histology, MRI and  microtomography.   The   lack   of   BSP   significantly   delayed   the   filling   up   of   the   defect  respective to wild­type controls, confirming the impairment of bone formation (data to be  published). Surprisingly with such low BFR, trabecular bone volume is higher (~30%) in 4  month   old   BSP­/­   long   bones   than   in   wild   type   (Figure   1c),   indicating   a   concommitant  reduction of bone resorption. Osteoclast surfaces and numbers are indeed reduced in mutant  mice (Figure 1d), and impaired osteoclast differentiation from BSP­/­ spleen and marrow cells 

ujm-00374655, version 1 - 9 Apr 2009

was confirmed in vitro  [27], in accordance with previous studies [33, 34]. We then asked  whether   the   low   turnover   phenotype   of   mutant   mice   could   be   increased   by   a   classical  challenge. BSP­/­ and wild type mice of both sexes were submitted to hindlimb unloading  through tail suspension for 2 to 3 weeks. We found that, contrarily to the OPN knockout [24],  mice lacking BSP lose bone under unloading, with increased BFR and osteoclast surfaces  [27]. In conclusion, BSP knockout impairs body and long bone growth and bone repair, but induces  a   high   trabecular   bone   mass   with   low   bone   turnover   that   is,   nonetheless,   responsive   to  mechanical   challenges.   These   data   clearly   contrast   with   the   phenotype   of   OPN   knockout  bone, and highlight the specificity of BSP roles in the bone context, and on a larger scale the  nonredundancy of function of SIBLING family members in skeletal biology.


This  work  was  funded by the Canadian  Institutes  of Health  Research  (FRN83704 to J.E.  Aubin) and by the Institut National de la Santé et de la Recherche Médicale (INSERM) and  the  Centre  National  de la Recherche Scientifique  (CNRS), through both basal funding  to  affiliated laboratories and a collective grant within the Ingénierie Tissulaire­Biomécanique­ Biomatériaux   (IT2B)   INSERM/CNRS   cooperative   program.   We   gratefully   aknowledge 

ujm-00374655, version 1 - 9 Apr 2009

additional funding from the Société Française de Rhumatologie through a phD scholarship.


Figure 1. Bone phenotype of BSP­/­ mice. (a) Pictures of BSP knockout (­/­) and wild type  (+/+) mice ; (b) whole radiography and (c) cortical 2D microtomography of isolated femurs  from   +/+   and   ­/­   mice   ;   (d)   quantification   of   bone   formation   rate   (BFR)   and   osteoclast  surfaces (Oc.S/BS) in the tibial trabecular bone of +/+ and ­/­ mice ; (e) 3D microtomographic  reconstruction of trabecular bone in the metaphysis of  +/+ and ­/­ femurs. The original data  were  published   in  Malaval   et   al.,   J   Exp   Med   205:1145­1153  ­   Copyright   belongs   to   the 

ujm-00374655, version 1 - 9 Apr 2009





Fisher LW, Fedarko NS (2003) Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44 Suppl 1:33-40.


Rowe PS (2000) The molecular background to hypophosphataemic rickets. Arch Dis Child 83:192-4.


MacDougall M, Simmons D, Gu TT, Dong J (2002) MEPE/OF45, a new dentin/bone

ujm-00374655, version 1 - 9 Apr 2009

matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21. Connect Tissue Res 43:320-30. 4.

Kawasaki K, Suzuki T, Weiss KM (2004) Genetic basis for the evolution of vertebrate mineralized tissue. Proc Natl Acad Sci U S A 101:11356-61.


Sire JY, Delgado S, Fromentin D, Girondot M (2005) Amelogenin: lessons from evolution. Arch Oral Biol 50:205-12.


Sullivan MM, Sage EH (2004) Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol 36:991-6.


Bradshaw AD, Sage EH (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107:1049-54.


Huq NL, Cross KJ, Ung M, Reynolds EC (2005) A review of protein structure and gene organisation for proteins associated with mineralised tissue and calcium phosphate stabilisation encoded on human chromosome 4. Arch Oral Biol 50:599-609.


Rowe PS (2004) The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15:264-81.



Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS (2008) Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757-72.


Qin C, Baba O, Butler WT (2004) Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 15:126-36.


Ogbureke KU, Fisher LW (2004) Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 83:664-70.

ujm-00374655, version 1 - 9 Apr 2009


Ogbureke KU, Fisher LW (2005) Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68:155-66.


Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212-26.


Ling Y, Rios HF, Myers ER, Lu Y, Feng JQ, Boskey AL (2005) DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res 20:2169-77.


Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-5.


Harris SE, Gluhak-Heinrich J, Harris MA, Yang W, Rowe PSN, Xie Y, Rios H, Zhang S, McKee MD, Bonewald LF, Feng JQ (2005) MEPE is overexpressed in osteocytes of the DMP1 (dentin matrix protein 1) null mouse, contributing to the hypophosphatemia and osteomalacia. Journal of Bone and Mineral Research 20:S178S79.



Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA (2003) Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998-2007.


Quarles LD (2003) Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112:642-6.


Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11:279-303.

ujm-00374655, version 1 - 9 Apr 2009


Patarca R, Saavedra RA, Cantor H (1993) Molecular and cellular basis of genetic resistance










activation-1/osteopontin gene. Crit Rev Immunol 13:225-46. 22.

Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101-11.


Yoshitake H, Rittling SR, Denhardt DT, Noda M (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A 96:8156-60.


Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M (2001) Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 193:399-404.


Harmey D, Johnson KA, Zelken J, Camacho NP, Hoylaerts MF, Noda M, Terkeltaub R, Millan JL (2006) Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res 21:1377-86.



Ganss B, Kim RH, Sodek J (1999) Bone sialoprotein. Crit Rev Oral Biol Med 10:79-98.


Malaval L, Wade-Gueye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amedee J, Vico L, Rossant J, Aubin JE (2008) Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 205:1145-53.


Hunter GK, Goldberg HA (1994) Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of

ujm-00374655, version 1 - 9 Apr 2009

hydroxyapatite by bone sialoprotein. Biochem J 302 ( Pt 1):175-9. 29.

Gorski JP (1998) Is all bone the same? Distinctive distributions and properties of noncollagenous matrix proteins in lamellar vs. woven bone imply the existence of different underlying osteogenic mechanisms. Crit Rev Oral Biol Med 9:201-23.


Gorski JP, Wang A, Lovitch D, Law D, Powell K, Midura RJ (2004) Extracellular bone acidic glycoprotein-75 defines condensed mesenchyme regions to be mineralized and localizes with bone sialoprotein during intramembranous bone formation. J Biol Chem 279:25455-63.


Midura RJ, Wang A, Lovitch D, Law D, Powell K, Gorski JP (2004) Bone acidic glycoprotein-75 delineates the extracellular sites of future bone sialoprotein accumulation and apatite nucleation in osteoblastic cultures. J Biol Chem 279:25464-73.


Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA (2007) Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 41:462-73.


Raynal C, Delmas PD, Chenu C (1996) Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 137:2347-54.



Valverde P, Tu Q, Chen J (2005) BSP and RANKL induce osteoclastogenesis and

ujm-00374655, version 1 - 9 Apr 2009

bone resorption synergistically. J Bone Miner Res 20:1669-79.



ujm-00374655, version 1 - 9 Apr 2009

Recommend Documents
Nov 9, 2016 - Matrix: Purified IgY; PBS pH 7.4. Specificity: Human Bone Sialoprotein. There was no cross reactivity obtained with human. Osteonectin, human ...

Nov 9, 2016 - sialoprotein and osteopontin in breast cancer bone metastases. Clin ... expression in osseous metastasized renal cell carcinomas and the.

Bone Sialoprotein is a phosphorylated glycoprotein that comprises 12% of the total ... standards and with the antibody coated on the wells of the microtiter plate.

CT scans. Three observers, blinded to the reconstruction algorithm used, compared both algorithms ... because of the high radiation dose and long examination.

Jun 3, 1999 - The design of complex parallel algorithms relies heavily on a set of primitive ... The Bulk-Synchronous Parallel (BSP) model of computation has ...

Sep 21, 2014 - The 30 Watt LSS panel is designed to fulfill an ever-growing need for portable, damage-resistant solar modules. Backed by a stainless steel ...

among co-resident children and how this affects school enrollment for children in. Burkina Faso. ...... Princeton University Ph.D. Dissertation. Butcher, Kristin and ...

Feb 2, 2015 - School of Medicine, University of Miami, Interdisciplinary Stem Cell Institute,. 1501 NW 10th ... 2015 Rodriguez-Menocal et al.; licensee BioMed Central. This is an ..... could be that WBM and BMC contained cells more cap-.

bone geometric structure and trabecular microstructure in the proximal tibial metaphysis than OVX. Keywords Osteoporosis . Ovariectomy . Spinal cord injury.

tion, 3) periosteum destruction, bone marrow preser- .... from the medial condyle to the osteotomy site and the ... Statistical analysis of the transformed data.